PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

Core Viewpoint - Prelude Therapeutics Incorporated is under investigation by the Schall Law Firm for potential violations of securities laws, particularly regarding misleading statements and failure to disclose critical information to investors [1][2]. Company Summary - The investigation centers on Prelude's announcement to pause the clinical development of its SMARCA2 degrader program, which was made on November 4, 2025. This decision was based on a thorough review of clinical data and an assessment of resource allocation compared to other programs [2]. - Following the announcement, Prelude's shares experienced a significant decline, falling by approximately 55.8% on the same day [2]. Legal Context - The Schall Law Firm is encouraging shareholders who have suffered losses to participate in the investigation and is offering free consultations regarding their rights [3].